uniQure announced June 17, 2026: FDA agreed that 3-year AMT-130 Phase I/II data supports an accelerated approval BLA for Huntington’s disease. BLA submission planned Q3 2026.
Huntington’s Disease Gene Therapy AMT-130 Is on Track for FDA Approval After uniQure Reaches Regulatory Agreement
by | Jun 19, 2026 | Uncategorized | 0 comments
Recent Comments